These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2513139)

  • 41. Transforming growth factor-beta in in vivo resistance.
    Teicher BA; Holden SA; Ara G; Chen G
    Cancer Chemother Pharmacol; 1996; 37(6):601-9. PubMed ID: 8612316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors.
    Eder JP; Antman K; Elias A; Shea TC; Teicher B; Henner WD; Schryber SM; Holden S; Finberg R; Chritchlow J
    J Natl Cancer Inst; 1988 Oct; 80(15):1221-6. PubMed ID: 3138431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
    Huitema AD; Kerbusch T; Tibben MM; Rodenhuis S; Beijnen JH
    Cancer Chemother Pharmacol; 2000; 46(2):119-27. PubMed ID: 10972481
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclocreatine in cancer chemotherapy.
    Teicher BA; Menon K; Northey D; Liu J; Kufe DW; Kaddurah-Daouk R
    Cancer Chemother Pharmacol; 1995; 35(5):411-6. PubMed ID: 7850923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio.
    Rockwell S; Nierenburg M; Irvin CG
    Cancer Treat Rep; 1987 Oct; 71(10):927-34. PubMed ID: 3652056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
    van Maanen MJ; Huitema AD; Rodenhuis S; Beijnen JH
    Anticancer Drugs; 2001 Jul; 12(6):519-24. PubMed ID: 11459998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of DNA repair and the enhancement of cytotoxicity of alkylating agents.
    Frankfurt OS
    Int J Cancer; 1991 Jul; 48(6):916-23. PubMed ID: 1907257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
    O'Dwyer PJ; LaCreta F; Nash S; Tinsley PW; Schilder R; Clapper ML; Tew KD; Panting L; Litwin S; Comis RL
    Cancer Res; 1991 Nov; 51(22):6059-65. PubMed ID: 1933869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
    Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
    Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
    Fujimoto S; Chikazawa H
    Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital.
    Campbell AD; Cohn SL; Reynolds M; Seshadri R; Morgan E; Geissler G; Rademaker A; Marymount M; Kalapurakal J; Haut PR; Duerst R; Kletzel M
    J Clin Oncol; 2004 Jul; 22(14):2885-90. PubMed ID: 15254057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
    Papadopoulou MV; Ji M; Bloomer WD
    Oncol Res; 2003; 13(12):561-6. PubMed ID: 12899246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
    Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS
    Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
    J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
    Rodenhuis S; Westermann A; Holtkamp MJ; Nooijen WJ; Baars JW; van der Wall E; Slaper-Cortenbach IC; Schornagel JH
    J Clin Oncol; 1996 May; 14(5):1473-83. PubMed ID: 8622061
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.
    Teicher BA; Waxman DJ; Holden SA; Wang YY; Clarke L; Alvarez Sotomayor E; Jones SM; Frei E
    Cancer Res; 1989 Sep; 49(18):4996-5001. PubMed ID: 2504483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
    Liebmann JE; Fisher J; Teague D; Cook JA
    Oncol Res; 1994; 6(1):25-31. PubMed ID: 7919549
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.